Pfizer / Antimicrobial-resistance fund, page-12

Notice today's partnership/licensing deal between Pfizer and tiny biotech, Voyager Therapeutics (VYGR). It makes me sick knowing this is EXACTLY the type of deal that ATH needs to do for the development and treatment of antibiotic resistance with PBT2 and/or other molecules but can't get done. I do understand that it's quite a bit more complicated and takes more time but, come-on guys, the clock is ticking. Get it done!! I'd like to know exactly who at Alterity is working on this $8 Billion dollar/year project or are they way too busy trying to get ATH 434 to Phase2 Trial and don't have the resources or manpower to aggressively pursue this tremendous opportunity. I'm real disappointed with Kempler, Stamler, and especially Sinclair who should have the reputation, cache, contacts, resources, and ability to make it happen. Frustrating and sickening...